Back to results
US 12,442,824 B2Granted
Assays for determining plasma kallikrein system biomarkers
AssigneeTakeda Pharmaceutical Company Limited
InventorsDaniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
Life of this patent
Estimating the term…
Abstract
Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
Claims9
A method for assessing plasma activation, comprising:
- providing a plasma sample from a subject;
- incubating the plasma sample with an activator of plasma kallikrein (pKal), wherein the activator is Factor XIIa (FXIIa) and wherein the activator is added ex vivo;
- and
- measuring the level of cleaved high molecular weight kininogen (HMWK) in the plasma sample after ex vivo activation;
- wherein the subject has been treated with a pKal inhibitor.
2 more elements
Dependencies are inferred from the claim text.